Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Morrow

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2017
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after ImmunotherapyMatthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, et al.
The Laryngoscope|August 9, 2025
DNA Immunotherapy (INO-3107) Results in Long-Term Surgery Reduction in RRPMilan R Amin, Peter C Belafsky, Simon R Best, et al.
Vaccines|February 5, 2020
Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory PapillomatosisCharu Aggarwal, Roger B Cohen, Matthew P Morrow, et al.
Journal for Immunotherapy of Cancer|July 7, 2021
Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumorsRobert H Vonderheide, Kimberly A Kraynyak, Anthony F Shields, et al.
Frontiers in Immunology|December 1, 2025
Safety, tolerability, and immunogenicity of a DNA-based vaccine (INO-4700) against Middle East respiratory syndrome coronavirus: phase 2a study in healthy volunteersJoseph T Agnes, Sarah A Marcus, Sahem S Al-Ghraibeh, et al.
Science Translational Medicine|October 12, 2012
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responsesMark L Bagarazzi, Jian Yan, Matthew P Morrow, et al.
Molecular Therapy Oncolytics|January 6, 2017
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100Matthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, et al.
The Journal of Infectious Diseases|March 21, 2019
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy VolunteersPablo Tebas, Kimberly A Kraynyak, Ami Patel, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 19, 2022
Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) InfectionJeffrey M Jacobson, David Zahrieh, Carrie A Strand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2018
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck CancerCharu Aggarwal, Roger B Cohen, Matthew P Morrow, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2017
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after ImmunotherapyMatthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, et al.
The Laryngoscope|August 9, 2025
DNA Immunotherapy (INO-3107) Results in Long-Term Surgery Reduction in RRPMilan R Amin, Peter C Belafsky, Simon R Best, et al.
Vaccines|February 5, 2020
Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory PapillomatosisCharu Aggarwal, Roger B Cohen, Matthew P Morrow, et al.
Journal for Immunotherapy of Cancer|July 7, 2021
Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumorsRobert H Vonderheide, Kimberly A Kraynyak, Anthony F Shields, et al.
Frontiers in Immunology|December 1, 2025
Safety, tolerability, and immunogenicity of a DNA-based vaccine (INO-4700) against Middle East respiratory syndrome coronavirus: phase 2a study in healthy volunteersJoseph T Agnes, Sarah A Marcus, Sahem S Al-Ghraibeh, et al.
Science Translational Medicine|October 12, 2012
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responsesMark L Bagarazzi, Jian Yan, Matthew P Morrow, et al.
Molecular Therapy Oncolytics|January 6, 2017
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100Matthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, et al.
The Journal of Infectious Diseases|March 21, 2019
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy VolunteersPablo Tebas, Kimberly A Kraynyak, Ami Patel, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 19, 2022
Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) InfectionJeffrey M Jacobson, David Zahrieh, Carrie A Strand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2018
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck CancerCharu Aggarwal, Roger B Cohen, Matthew P Morrow, et al.
Pageof 5